Information de reference pour ce titreAccession Number: | 01244665-200807000-00006.
|
Author: | Zubaid, Mohammad; Shakir, Douraid K; Bazargani, Nooshin; Binbrek, Azan; Gopal, Raj; Al-Tamimi, Omar; Bakir, Sherif
|
Institution: | (a)Department of Medicine, Faculty of Medicine, Kuwait University, Division of Cardiology, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait (b)Hamad Medical Corporation, Cardiology Department, Qatar (c)Department of Medicine, Faculty of Medicine, WCMC-Q, Doha, Qatar (d)Dubai Hospital, Dubai, UAE (e)Rashid Hospital, Dubai, UAE (f)Al-Ain Hospital, Al-Ain, UAE (g)Hamad Hospital, Doha, Qatar (h)Qassimi Hospital, Sharjah, UAE
|
Title: | |
Source: | Journal of Cardiovascular Medicine. 9(7):688-693, July 2008.
|
Abstract: | Objectives: To assess the efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia and coronary artery disease (CAD).
Design and setting: Prospective, multicentre, randomized, double-blind, placebo-controlled trial conducted in three Middle Eastern countries.
Patients: Patients with known CAD, who were being treated with simvastatin 20 mg and had low-density lipoprotein cholesterol (LDL-C) concentrations of 2.6 to 4.1 mmol/l, were randomized to receive daily coadministration of ezetimibe 10 mg or placebo.
Main outcome measures: The primary outcome was percentage reduction of LDL-C after 6 weeks of randomization. Secondary endpoints included number of patients who achieved National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C level and safety and tolerability.
Results: We enrolled 144 patients of whom 120 had blood available for final analysis. The coadministration of ezetimibe with ongoing simvastatin therapy resulted in a statistically significant additional reduction in LDL-C concentration as compared with simvastatin monotherapy (-26.7 versus -9.1%, respectively; total additional reduction of 17.6%, P < 0.0001). More patients in the ezetimibe and simvastatin group achieved NCEP ATP III LDL-C target levels than in the simvastatin monotherapy group (70 versus 33%, respectively; P = 0.0001). The coadministration of ezetimibe with simvastatin was well tolerated with a safety profile similar to that of simvastatin monotherapy.
Conclusion: When coadministered with simvastatin therapy, ezetimibe resulted in significant additional reduction in LDL-C and enabled more patients to achieve NCEP ATP III LDL-C target levels. This was achieved safely and with excellent tolerability.
(C) 2008 Italian Federation of Cardiology. All rights reserved.
|
Author Keywords: | cholesterol lowering; ezetimibe; lipid management.
|
References: | 1 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
2 De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003; 171:145-155.
3 Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
4 Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
5 Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
6 Topol EJ. Intensive statin therapy: a sea change in cardiovascular prevention. N Engl J Med 2004; 350:1562-1564.
7 Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001; 17:43-50.
8 Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19:355-371.
9 Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
10 Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283:157-163.
11 Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. Boston, MA: Little Brown; 1964. p. 114.
12 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
13 Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-2415.
14 Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-2134.
15 Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-467.
|
Language: | English.
|
Document Type: | Original articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1558-2027
|
NLM Journal Code: | 101259752
|
DOI Number: | https://dx.doi.org/10.2459/JCM.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|